title: Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions.
abstract: OBJECTIVE
  It has recently been proposed that anaemia is an independent risk factor for development of cardiovascular disease in the general population. The impact of anaemia on long-term survival of patients with manifest coronary heart disease (CHD) has not been assessed so far. In this study, we examined the influence of haemoglobin concentrations on the outcome after percutaneous coronary interventions (PCI).
  
  
  RESULTS
  In a retrospective cohort study, we analysed in-hospital and long-term mortality in all male patients admitted to our institution for elective PCI from 1998 to 1999. In 689 cases, complete follow-up information could be obtained (98.4%). Depending on their baseline haemoglobin, patients were divided in quintiles. In all subgroups, angiographic success after PCI (90-94%) was comparably high and in-hospital mortality was low (0-0.7%). During follow-up (median 697 days), patients in the lowest haemoglobin quintile (</=12.9g/dl) were significantly more likely to suffer from all-cause death (22.2%) than those of the other quintiles (3.7-12.1%; estimated mortality rates from Kaplan-Meier models, P<0.0001, log rank test). In more detail, we found a U-shaped relationship between mortality and haemoglobin strata in steps of 1g/dl (P<0.0001, log rank test). After adjustment for potential co-variates, patients of the lowest haemoglobin quintile showed in Cox regression analysis a markedly higher risk for death (adjusted hazard rate ratio (HRR) 4.09, 95% confidence interval (CI) 1.52-11.05) compared to the quintile with a haemoglobin concentration of 14.6-15.2g/dl.
  
  
  CONCLUSIONS
  These results indicate that anaemia is associated with markedly reduced survival in patients with CHD after elective PCI. Since PCI is a common intervention and anaemia is a frequent condition in the general population, strategies for the management of anaemic PCI patients and treatment of anaemic patients with CHD should be developed.
authors.affiliation: Medizinische Klinik und Poliklinik C (Department of Cardiology and Angiology), Hospital of the University of Münster, Münster, Germany. reinech@uni-muenster.de
authors.forename: Holger
authors.initials: H
authors.lastname: Reinecke
authors.forename: Torsten
authors.initials: T
authors.lastname: Trey
authors.forename: Jürgen
authors.initials: J
authors.lastname: Wellmann
authors.forename: Jan
authors.initials: J
authors.lastname: Heidrich
authors.forename: Manfred
authors.initials: M
authors.lastname: Fobker
authors.forename: Thomas
authors.initials: T
authors.lastname: Wichter
authors.forename: Michael
authors.initials: M
authors.lastname: Walter
authors.forename: Günter
authors.initials: G
authors.lastname: Breithardt
authors.forename: Roland M
authors.initials: RM
authors.lastname: Schaefer
mesh_terms: D000704:Analysis of Variance; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000401:mortality*; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality*; D002423:Cause of Death; D015331:Cohort Studies; D003327:Coronary Disease / Q000097:blood / Q000401:mortality / Q000628:therapy*; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis*; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D013781:Texas / Q000453:epidemiology
chemical_list: D006454:Hemoglobins